<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35315">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131220</url>
  </required_header>
  <id_info>
    <org_study_id>Zhongshan 2012-134</org_study_id>
    <nct_id>NCT02131220</nct_id>
  </id_info>
  <brief_title>Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction</brief_title>
  <acronym>RECOVERII</acronym>
  <official_title>Effects of Intracoronary Prourokinase or Tirofiban on the Coronary Flow During Primary Percutaneous Coronary Intervention for the Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intracoronary selective thrombolysis are
      more effective than tirofiban on the coronary flow during primary  percutaneous coronary
      intervention for the acute myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Coronary flow using corrected Thrombolysis In Myocardial Infarction Frame Count (cTFC)</measure>
    <time_frame>At the end of Percutaneous Coronary Intervention procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST segment resolution in ECG</measure>
    <time_frame>3 hours post PCI procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak troponin T level</measure>
    <time_frame>in the 7 days post PCI procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma N terminal-proBNP levels</measure>
    <time_frame>1 and 30 days post PCI procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infarction area confirmed by SPECT</measure>
    <time_frame>30 days post PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of major adverse cardiac events (MACE) defined as the composite of death, myocardial infarction and target vessel revascularization</measure>
    <time_frame>30 days post PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>TIMI defined total major bleeding</measure>
    <time_frame>30 days post PCI</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Thrombolytic Therapy</condition>
  <arm_group>
    <arm_group_label>Prourokinase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracoronary bolus infusion of 20mg prourokinase using selective catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirofiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracoronary bolus infusion using selective catheter (10ug/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prourokinase</intervention_name>
    <description>20mg intracoronary bolus infusion using selective catheter during PCI</description>
    <arm_group_label>Prourokinase</arm_group_label>
    <other_name>Reocmbinant Human Prourokinase for Injection</other_name>
    <other_name>TIANJIN TASLY PHARMACEUTICAL CO.,LTD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban</intervention_name>
    <description>10ug/kg intracoronary bolus infusion using selective catheter during PCI</description>
    <arm_group_label>Tirofiban</arm_group_label>
    <other_name>Grand Pharmr (China) Co. Ltd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST-segment elevation AMI within 12 hours of symptom onset

        Exclusion Criteria:

          -  Contraindications to thrombolysis or PCI

          -  Patients administered a fibrinolytic agent before PCI

          -  Patients enrolled in clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Huang, M.D.</last_name>
    <phone>862113512142875</phone>
    <email>huang.dong@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Huang, M.D.</last_name>
      <phone>862113512142875</phone>
      <email>huang.dong@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Dong Huang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 3, 2014</lastchanged_date>
  <firstreceived_date>May 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ge Junbo</investigator_full_name>
    <investigator_title>Director, Dept. of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital</investigator_title>
  </responsible_party>
  <keyword>No-Reflow Phenomenon</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saruplase</mesh_term>
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
